These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30641816)

  • 1. Predictive value of non-HDL cholesterol for cardiovascular disease in a population in far western Algeria with type 2 diabetes.
    Kachekouche Y; Dali-Sahi M; Bendaoud R; Dennouni-Medjati N; Abderahim M
    Diabetes Metab Syndr; 2019; 13(1):826-829. PubMed ID: 30641816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-HDL cholesterol predictive factor of type 2 diabetes in the city of Tlemcen.
    Dali-Sahi M; Kachekouche Y; Dennouni-Medjati N; Nafuye G
    Diabetes Metab Syndr; 2019; 13(1):518-521. PubMed ID: 30641757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of dyslipidemia and evaluation of non-HDL cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus.
    Pandeya A; Sharma M; Regmi P; Basukala A; Lamsal M
    Nepal Med Coll J; 2012 Dec; 14(4):278-82. PubMed ID: 24579534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease.
    El-Lebedy D; Raslan HM; Mohammed AM
    Cardiovasc Diabetol; 2016 Jan; 15():12. PubMed ID: 26800892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes.
    Modi KD; Chandwani R; Ahmed I; Kumar KV
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S99-S102. PubMed ID: 26589777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study.
    Lu W; Resnick HE; Jablonski KA; Jones KL; Jain AK; Howard WJ; Robbins DC; Howard BV
    Diabetes Care; 2003 Jan; 26(1):16-23. PubMed ID: 12502653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HDL cholesterol and cardiovascular disease in a population with hypertension and type 2 diabetes mellitus. RICARHD Study].
    Conthe P; Gómez-Fernández P; de Alvaro F; Fernández-Pérez C; González-Esteban J; Cea-Calvo L;
    Rev Clin Esp; 2009 May; 209(5):227-33. PubMed ID: 19480779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as Predictors of Cardiovascular Disease in Chinese.
    Gu X; Yang X; Li Y; Cao J; Li J; Liu X; Chen J; Shen C; Yu L; Huang J; Gu D
    Am J Cardiol; 2015 Oct; 116(7):1063-70. PubMed ID: 26250998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.
    Malave H; Castro M; Burkle J; Voros S; Dayspring T; Honigberg R; Pourfarzib R
    Am J Cardiol; 2012 Sep; 110(5):662-5. PubMed ID: 22621796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
    Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
    Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease.
    Zelber-Sagi S; Salomone F; Yeshua H; Lotan R; Webb M; Halpern Z; Santo E; Oren R; Shibolet O
    Liver Int; 2014 Jul; 34(6):e128-35. PubMed ID: 24118857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk.
    Milwidsky A; Kivity S; Kopel E; Klempfner R; Berkovitch A; Segev S; Sidi Y; Goldenberg I; Maor E
    Int J Cardiol; 2014 May; 173(2):295-9. PubMed ID: 24681020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: Subanalysis of the MEGA study.
    Sone H; Nakagami T; Nishimura R; Tajima N;
    Diabetes Res Clin Pract; 2016 Mar; 113():14-22. PubMed ID: 26972955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.